Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions

Genes Chromosomes and Cancer - Tập 58 Số 8 - Trang 578-588 - 2019
Albrecht Stenzinger1, Jeffrey D. Allen2, J. Maas3, Mark Stewart2, Diana M. Merino2, Madison M. Wempe2, Manfred Dietel4
1Institute of Pathology, University Hospital Heidelberg (on behalf of QuIP® GmbH, Berlin, Germany) Heidelberg Germany
2Science Policy, Friends of Cancer Research Washington District of Columbia
3Management Department QuIP® GmbH Berlin Germany
4Institute of Pathology, Charité Berlin (on behalf of QuIP® GmbH, Berlin, Germany) Berlin Germany

Tóm tắt

AbstractCharacterization of tumors utilizing next‐generation sequencing methods, including assessment of the number of somatic mutations (tumor mutational burden [TMB]), is currently at the forefront of the field of personalized medicine. Recent clinical studies have associated high TMB with improved patient response rates and survival benefit from immune checkpoint inhibitors; hence, TMB is emerging as a biomarker of response for these immunotherapy agents. However, variability in current methods for TMB estimation and reporting is evident, demonstrating a need for standardization and harmonization of TMB assessment methodology across assays and centers. Two uniquely placed organizations, Friends of Cancer Research (Friends) and the Quality Assurance Initiative Pathology (QuIP), have collaborated to coordinate efforts for international multistakeholder initiatives to address this need. Friends and QuIP, who have partnered with several academic centers, pharmaceutical organizations, and diagnostic companies, have adopted complementary, multidisciplinary approaches toward the goal of proposing evidence‐based recommendations for achieving consistent TMB estimation and reporting in clinical samples across assays and centers. Many factors influence TMB assessment, including preanalytical factors, choice of assay, and methods of reporting. Preliminary analyses highlight the importance of targeted gene panel size and composition, and bioinformatic parameters for reliable TMB estimation. Herein, Friends and QuIP propose recommendations toward consistent TMB estimation and reporting methods in clinical samples across assays and centers. These recommendations should be followed to minimize variability in TMB estimation and reporting, which will ensure reliable and reproducible identification of patients who are likely to benefit from immune checkpoint inhibitors.

Từ khóa


Tài liệu tham khảo

10.1126/science.aaa4971

10.1038/nature12477

10.1038/nature12213

10.1186/s13073-017-0424-2

10.7150/thno.21471

10.1093/annonc/mdw217

10.1038/nature07943

10.1158/1078-0432.CCR-16-0903

10.1016/j.celrep.2016.03.075

10.1038/nrc3239

10.1073/pnas.192461099

Nobel MediaAB. The Nobel Prize in Physiology or Medicine2018.https://www.nobelprize.org/prizes/medicine/2018/press-release/. Accessed October 2 2018.

10.1056/NEJMc1713444

10.21037/atm.2016.07.11

10.1126/science.aaa8172

10.1126/science.aaa1348

10.1016/j.jtho.2016.11.343

10.1056/NEJMoa1613493

Cristescu R, 2017, Mutational load (ML) and T‐cell‐inflamed microenvironment as predictors of response to pembrolizumab, J Clin Oncol, 35

FabrizioD LieberD MalboeufC et al. A blood‐based next‐generation sequencing assay to determine tumor mutational burden (bTMB) is associated with benefit to an anti‐PD‐L1 inhibitor atezolizumab. Presented at: AACR Annual Meeting; April 14–18 2018; Chicago IL.Cancer Res.2018;78(13 suppl). Abstract 5706.

10.1056/NEJMoa1801946

Ramalingam SS, 2018, Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first‐line (1L) non‐small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568, Cancer Res, 78

Velcheti V, 2018, Prospective clinical evaluation of blood‐based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non‐small cell lung cancer (NSCLC): interim B‐F1RST results, J Clin Oncol, 36, 10.1200/JCO.2018.36.15_suppl.12001

10.1038/s41591-018-0134-3

10.1093/annonc/mdy495

10.1016/S0140-6736(16)00561-4

10.1016/S0140-6736(16)32455-2

10.1016/j.ccell.2018.03.018

HelwickC. KEYNOTE trial data suggest features predicting response to pembrolizumab; 2017.http://www.ascopost.com/issues/march-25-2017/keynote-trial-data-suggest-features-predicting-response-to-pembrolizumab/. Accessed October 10 2018.

NIH.ClinicalTrials.gov.https://clinicaltrials.gov/ct2/home. Accessed October 10 2018.

10.1126/science.aar3593

10.3390/cancers7030859

10.1038/nm.4333

FDA. FoundationOne CDx: summary of safety and effectiveness data (SSED); 2017.https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf. Accessed October 10 2018.

FDA. FDA announces approval CMS proposes coverage of first breakthrough‐designated test to detect extensive number of cancer biomarkers; 2017.https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm587273.htm. Accessed October 10 2018.

FDA. FDA unveils a streamlined path for the authorization of tumor profiling tests alongside its latest product action; 2017.https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm585347.htm. Accessed October 10 2018.

Galsky MD, 2017, Impact of tumor mutation burden on nivolumab efficacy in second‐line urothelial carcinoma patients: exploratory analysis of the phase II CheckMate 275 study, Ann Oncol, 28

10.1016/j.ccell.2018.04.001

10.1016/j.cell.2017.09.028

10.1007/s00428-016-2025-7

IQN Path. International quality network for pathology. Annual report; 2017.http://www.iqnpath.org/wp-content/uploads/2018/04/IQNPath_AnnualReport2017-26032018.pdf. Accessed October 10 2018.

Krieken H, 2016, Quality to rely on: meeting report of the 5th Meeting of External Quality Assessment, Naples 2016, ESMO Open, 1, e000114, 10.1136/esmoopen-2016-000114

Friends of Cancer Research. Tumor mutational burden (TMB); 2018.https://www.focr.org/tmb. Accessed October 10 2018.

EnzlbergerN. Tumor mutational burden (TMB): QuIP organises a study and liaises with FoCR; 2018.https://wp.quip.eu/en_GB/2018/05/14/tumor‐mutational‐burden‐tmb‐quip‐organisiert‐studie‐und‐arbeitet‐mit‐focr‐zusammen/. Accessed October 10 2018.

10.1126/science.aaf1490

10.1056/NEJMoa1113205

10.1016/j.ccell.2018.07.001

10.1111/cge.12257

10.1200/JCO.2017.35.15_suppl.e23028

Ma M, 2015, “Liquid biopsy”—ctDNA detection with great potential and challenges, Ann Transl Med, 3, 235

10.1016/j.jtho.2018.05.030

10.1186/s12885-018-4199-7

10.1200/JCO.2017.76.8671

10.1158/1078-0432.CCR-17-1439

10.5858/arpa.2016-0117-RA

10.1016/j.jmoldx.2017.01.011

10.1016/S0002-9440(10)64472-0

10.1371/journal.pone.0176280

10.1016/j.ymeth.2014.01.022

10.1038/srep37984

10.3390/ijms17050651

Baras AS, 2017, Characterization of total mutational burden in the GENIE cohort: small and large panels can provide TMB information but to varying degrees, Cancer Res, 77

10.1186/s13073-016-0333-9

10.1016/j.jmoldx.2017.06.001

10.18632/oncotarget.24353

10.1038/nature08250

10.1002/ijc.31878

10.21037/tlcr.2018.08.14

Endris V, 2018, Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in‐silico and real‐life analysis of three larger gene panels, Int J Cancer

10.1016/j.jmoldx.2013.05.003

10.1371/journal.pone.0151664

10.1371/journal.pone.0188174

10.1038/s41467-017-01460-0

10.1038/ncomms1814

10.1016/j.cell.2017.09.048

10.18632/oncotarget.17225

10.1038/nbt.2696

10.1038/bjc.2015.233

Thông tin
Thông tin xuất bản

Genes Chromosomes and Cancer

Tập 58 Số 8

578-588

Thông tin tác giả